Background
The concept of essential fatty acids was established by Burr and Burr (1929–1930), who demonstrated that fat-free diets produced deficiency syndromes in rats, later attributed to LA and alpha-linolenic acid. Widespread industrialization of vegetable oil production during the 20th century substantially increased dietary LA intake in Western populations, widening the omega-6:omega-3 ratio relative to pre-industrial diets. From the 1960s onward, dietary fat research focused heavily on replacing saturated fats with polyunsaturated fats for cardiovascular benefit, with LA-rich oils promoted accordingly. Since the 1990s, debate has shifted toward the importance of the omega-6:omega-3 balance—driven by Simopoulos and others—and toward identifying specific roles for GLA, DGLA, and AA in immune and inflammatory regulation.
Evidence snapshot
Linoleic acid (LA) is an essential fatty acid: the body cannot synthesize it, so it must come from food. Metabolic studies confirm LA is incorporated into cell membrane phospholipids and serves as the precursor for longer-chain n-6 metabolites, including arachidonic acid (AA), which generates eicosanoids (prostaglandins, leukotrienes) that regulate inflammation, platelet aggregation, and vasomotor tone.
Evidence from randomized trials and large cohort studies on cardiovascular outcomes is mixed. Multiple meta-analyses indicate that replacing saturated fat with polyunsaturated fat (predominantly LA) reduces coronary heart disease events. However, reanalysis of older trials—most notably Ramsden et al. (BMJ, 2013)—raised questions about heterogeneity in outcomes and the potential role of AA-derived mediators, underscoring that not all n-6 interventions are equivalent.
Supplemental gamma-linolenic acid (GLA), found in evening primrose oil and borage oil, has been tested in atopic dermatitis and inflammatory conditions. A Cochrane systematic review (2013) found inconsistent evidence of benefit for eczema, with modest effect sizes and methodological limitations across trials. For arthritis and other inflammatory conditions, results similarly remain inconclusive. The omega-6:omega-3 ratio is an increasingly studied determinant of net inflammatory tone.
Bioavailability and metabolism
Dietary LA from whole foods and oils is efficiently absorbed and rapidly incorporated into plasma lipoproteins and tissue phospholipids. Conversion efficiency from LA to GLA, DGLA, and ultimately AA is limited by Δ6-desaturase activity, which is the rate-limiting step in the pathway. This enzyme is downregulated by aging, high insulin resistance, alcohol intake, zinc deficiency, and competing omega-3 substrates. Supplemental GLA bypasses the Δ6-desaturase step entirely, leading to more predictable increases in DGLA concentrations—which is one rationale for GLA supplementation in conditions where DGLA-derived anti-inflammatory mediators are therapeutically targeted.
Populations studied and outcomes
Cardiovascular disease: Multiple pooled analyses of cohort data and some randomized controlled trials support that replacing saturated fat with LA-rich polyunsaturated fats reduces coronary events. Evidence is strongest for LDL cholesterol reduction; effects on mortality and specific cardiovascular endpoints are more heterogeneous across trials. Atopic dermatitis: Randomized trials of evening primrose oil and borage oil have enrolled children and adults with eczema. A 2013 Cochrane review found inconsistent findings, small effect sizes, and methodological limitations; no firm clinical recommendation emerges from the aggregate evidence. Rheumatoid arthritis: Small trials of GLA from borage oil suggest modest reductions in joint tenderness and morning stiffness, but trials are underpowered and evidence is insufficient to support routine use.
Long-term safety and the omega-6:omega-3 balance
Dietary LA at levels meeting the IOM adequate intake is considered safe. The primary safety concern with omega-6 fatty acids is not toxicity but imbalance: Western dietary patterns characterized by high LA and low EPA/DHA intake produce elevated omega-6:omega-3 ratios (estimated at 15:1 to 20:1 in some populations, compared to an estimated ancestral ratio near 4:1). Epidemiological data associate high ratios with greater markers of inflammatory burden, though causality is difficult to establish given confounding dietary factors. The practical implication is that improving omega-3 intake (EPA/DHA from fish or algae, or ALA from flaxseed) is at least as important as managing omega-6 quantity.
Food sources, processing, and practical choices
Whole-food omega-6 sources—walnuts, sunflower seeds, flaxseed (also rich in ALA), and small amounts of unrefined plant oils—deliver LA alongside fiber, vitamin E, and phytonutrients. Refined seed oils (soybean, corn, sunflower) are concentrated LA sources widely used in commercial food processing and restaurant frying. Polyunsaturated fats oxidize more readily than saturated or monounsaturated fats at high temperatures, generating aldehydes and other oxidation products; for high-heat cooking, oils with lower polyunsaturated fat content (e.g., avocado or high-oleic sunflower oil) are more stable. Cold-pressed unrefined oils are better reserved for dressings or low-heat applications.
Compound variations
Linoleic acid (LA)
The primary dietary omega-6 and an essential fatty acid found in vegetable oils, nuts, and seeds. Serves as the precursor for all longer-chain n-6 metabolites.
Common use case
Meeting essential fatty acid requirements through diet.
Dosage note
Adequate intake: ~17 g/day (adult men), ~12 g/day (adult women) per IOM (2005). Dietary sources are preferred over supplemental isolates.
Gamma-linolenic acid (GLA)
A longer-chain n-6 fatty acid found in evening primrose, borage, and black currant seed oils. Bypasses the rate-limiting Δ6-desaturase step to increase DGLA concentrations.
Common use case
Adjunct use for atopic dermatitis or selected inflammatory conditions, where evidence is mixed.
Dosage note
Clinical trials have used approximately 80–320 mg GLA/day (via 1–3 g/day of oil). Confirm GLA content on the product label and evaluate response over 6–12 weeks.
Arachidonic acid (AA)
A long-chain n-6 fatty acid derived enzymatically from LA or consumed directly in animal products. Central substrate for 2-series prostaglandins and 4-series leukotrienes.
Common use case
Dietary intake via meat and eggs provides physiological AA. Supplemental AA is used in some infant formulas; routine supplementation in adults is not evidence-based.
Dosage note
Supplemental AA dosing is context-specific (e.g., infant formula standards). In adults, concentrated AA supplementation is not recommended without clinical indication.
Conjugated linoleic acid (CLA)
A group of linoleic acid isomers (structurally and functionally distinct from LA) found naturally in ruminant dairy and meat, and sold as a concentrated supplement for body composition.
Common use case
Short-term trials for modest body composition effects; overall evidence for meaningful benefit is limited.
Dosage note
Most human trials use 1.8–3.4 g/day of CLA. Effects on fat mass are modest and long-term safety data are limited.
Dosage and best practices
Dosage principles
- Dietary linoleic acid (LA) — adequate intake (AI): The Institute of Medicine (2005) sets AIs of approximately 17 g/day for adult men and 12 g/day for adult women. Values vary by age and life stage. Most people in Western diets meet or exceed these targets from food alone.
- Supplemental GLA (evening primrose oil, borage oil): Clinical trials have generally provided 1–3 g/day of oil, delivering approximately 80–320 mg/day of GLA. Trials that reported signals for atopic dermatitis or inflammatory conditions typically used GLA in the 240–320 mg/day range. Check product labels for actual GLA content, as it varies by oil source.
- Cardiovascular dietary replacement: Trials that substituted saturated fat with LA-rich oils typically raised LA to roughly 5–10% of total energy. These substitutions should be approached as dietary pattern changes rather than isolated supplementation, ideally with guidance from a clinician or registered dietitian.
Best practices
- Favor whole-food omega-6 sources—nuts, seeds, and small amounts of unrefined vegetable oil—over large quantities of refined seed oils prevalent in ultra-processed foods.
- Track omega-3 intake alongside omega-6: increasing LA without adequate EPA, DHA, or ALA shifts the competitive balance at shared enzymes and may alter eicosanoid profiles.
- When using GLA supplements, confirm the GLA content per serving on the label (not just the oil weight). Start at the lower end of the therapeutic range (~200 mg GLA/day) and evaluate symptoms over 6–12 weeks before adjusting dose.
Literature and references
Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids
Institute of Medicine (US) Report (NCBI Bookshelf) • 2005
Authoritative report establishing adequate intakes for linoleic acid and other fatty acids, with review of metabolism and dietary requirements.
The importance of the ratio of omega-6/omega-3 essential fatty acids
Biomedicine & Pharmacotherapy • 2002
A widely cited review by Simopoulos examining evolutionary shifts in dietary omega-6:omega-3 ratios and their proposed implications for chronic disease.
Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis
BMJ (Clinical research ed.) • 2013
Reanalysis of historical trial data and meta-analysis raising questions about the uniformity of benefit from increasing dietary linoleic acid, particularly when omega-3 status is low.
Fatty acids and the immune system: from basic science to clinical applications
The Proceedings of the Nutrition Society • 2004
Review of how fatty acids affect the immune system, focusing on the hypothesis that anti-inflammatory properties of n-3 PUFA in the arterial wall contribute to their protective effects in cardiovascular disease.
Borage oil and evening primrose oil for eczema
Cochrane Database of Systematic Reviews • 2013
Systematic review finding inconsistent and generally weak evidence for GLA-containing oils in atopic dermatitis, with a call for better-designed trials.
Common questions
Are omega-6 fatty acids pro-inflammatory?
Not categorically. Some AA-derived eicosanoids act as pro-inflammatory mediators, but other n-6 derivatives—particularly DGLA-derived 1-series prostaglandins—have anti-inflammatory properties. The inflammatory outcome depends on which n-6 metabolites predominate, which is influenced by enzyme activity, competing omega-3 intake, and overall dietary pattern.
How much linoleic acid do I need daily?
The IOM (2005) sets adequate intakes at approximately 17 g/day for adult men and 12 g/day for adult women, with variation by age and life stage. Most people following a typical Western diet already meet or exceed these levels through food alone.
Is there good evidence for evening primrose or borage oil for eczema?
A 2013 Cochrane systematic review found inconsistent evidence for benefit, with most trials showing small and statistically unreliable effects. If you choose to try GLA supplementation for atopic dermatitis, use a product with a known GLA content per serving and assess symptoms systematically over 6–12 weeks with your clinician.
Will eating more omega-6 reduce the effectiveness of my omega-3 supplements?
High omega-6 intake does compete with omega-3s for the same desaturase enzymes and membrane sites. Rather than eliminating recommended LA, most nutrition guidance prioritizes increasing EPA and DHA intake—through diet or supplements—to improve the ratio.
What are the risks of high-dose omega-6 supplements?
Concentrated oil supplements at high doses can cause gastrointestinal side effects. Individuals on anticoagulant or antiplatelet medications should consult a clinician before adding these supplements, as eicosanoid shifts may affect platelet function. People with seizure disorders should note case reports linking high-dose evening primrose oil to lowered seizure threshold.